<div id="readability-page-1"><div> By Connor Hart <pre></pre> Shares of Zymeworks and Jazz Pharmaceuticals climbed after the companies released what they called positive topline results from a late-stage trial of their treatment for certain cancers, including of the stomach, gastroesophageal junction and esophagus. Zymeworks' stock rose 59%, to $29.45, in premarket trading Monday, while Jazz Pharmaceuticals' stock gained 31%, to $184.99. Through Friday's close, shares of Zymeworks are up nearly 27% so far this year, and shares of Jazz Pharmaceuticals are up nearly 15%. The companies said before the bell that the safety profile of their treatment, zanidatamab-hrii, used in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma was generally consistent with the known safety profile of each agent. The recent trial results support the overall benefit-risk of the drug for use in this indication, the companies added. The companies expect to submit a supplemental biologics license application in the first half of 2026 to support zanidatamab-hrii as a first-line treatment. The treatment is currently approved in the U.S., Europe and China for use in second-line biliary tract cancer and is marketed under the trade name Ziihera. BeOne Medicines is helping to develop and commercialize the treatment. <pre></pre> Write to Connor Hart at connor.hart@wsj.com <pre></pre> (END) Dow Jones Newswires November 17, 2025 07:16 ET (12:16 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

爵士制藥

ZYME

Zymeworks 和爵士製藥的股票在宣佈其癌症治療藥物 zanidatamab-hrii 的積極三期臨牀試驗結果後大幅上漲。Zymeworks 的股價上漲了 59%，達到 29.45 美元，而爵士製藥的股價上漲了 31%，達到 184.99 美元。該治療與化療聯合用於 HER2 陽性胃食管腺癌，顯示出一致的安全性。兩家公司計劃在 2026 年提交補充生物製劑許可申請。該治療已在二線膽道癌中以 Ziihera 的名稱獲得批准

Zymeworks 和 Jazz Pharmaceuticals 的股價在癌症治療的三期試驗結果顯示積極後上漲